InvestSMART

Creso Pharma Limited (ASX: CPH) - Announcements

- Current share price for CPH : $0.009

ASX company news and announcements for Creso Pharma Limited (CPH) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Creso Pharma Limited (CPH) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Creso Pharma Limited (CPH), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Creso Pharma Limited (CPH)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Suspension from Official Quotation 4 Feb 2019 5:35PM $0.415 $0.009 fallen by 97.83%
- Cleansing Statement & Appendix 3B 1 Feb 2019 3:38PM $0.415 $0.009 fallen by 97.83%
- Trading Halt 1 Feb 2019 3:36PM $0.415 $0.009 fallen by 97.83%
- Pause In Trading 1 Feb 2019 3:01PM $0.415 $0.009 fallen by 97.83%
- Colombian Partnership and Appointment of Medical Advisor 1 Feb 2019 9:17AM $0.410 $0.009 fallen by 97.80%
- Quarterly Update & Appendix 4C 31 Jan 2019 4:06PM $0.410 $0.009 fallen by 97.80%
- Placement Update, Cleansing Statement & Appendix 3B 31 Jan 2019 9:51AM $0.475 $0.009 fallen by 98.11%
- Creso and CLV Expand the OBMJ Beers to Switzerland 30 Jan 2019 10:04AM $0.470 $0.009 fallen by 98.09%
- Creso Raises $3 Million in Institutional Placement 24 Jan 2019 9:17AM $0.540 $0.009 fallen by 98.33%
- Trading Halt 22 Jan 2019 9:12AM $0.540 $0.009 fallen by 98.33%
- Creso Signs Supply Agreement with TerrAscend Canada 21 Jan 2019 9:13AM $0.525 $0.009 fallen by 98.29%
- Creso further builds medical cannabis in NZ with Medleaf 9 Jan 2019 9:25AM $0.565 $0.009 fallen by 98.41%
- Strategic Collaboration in Sri Lanka for Medical Cannabis 7 Jan 2019 8:26AM $0.535 $0.009 fallen by 98.32%
- Creso builds on Israel's new Med Cannabis export law 2 Jan 2019 8:24AM $0.490 $0.009 fallen by 98.16%
- Settlement of Kunna Canada Acquisition - incl Appendix 3B 20 Dec 2018 7:04PM $0.350 $0.009 fallen by 97.43%
- US CBD hemp market opens to Creso 20 Dec 2018 9:30AM $0.340 $0.009 fallen by 97.35%
- Update on Creso Pharma Canadian growing facility 19 Dec 2018 8:26AM $0.340 $0.009 fallen by 97.35%
- Secondary Trading Notice & Appendix 3B 17 Dec 2018 7:00PM $0.360 $0.009 fallen by 97.50%
- Commercialisation of Animal Health Products Commences 17 Dec 2018 9:28AM $0.360 $0.009 fallen by 97.50%
- Canada TSX-V Roadshow Presentation 4 Dec 2018 9:01AM $0.425 $0.009 fallen by 97.88%
- Creso Pharma to Dual List on TSX-V Canada 3 Dec 2018 9:10AM $0.415 $0.009 fallen by 97.83%
- Interview with Creso COO 28 Nov 2018 3:49PM $0.415 $0.009 fallen by 97.83%
- Exclusive Distribution Agreement for CPH Veterinary Products 14 Nov 2018 8:23AM $0.445 $0.009 fallen by 97.98%
- Creso to launch its first medical cannabis product in Brazil 1 Nov 2018 8:22AM $0.415 $0.009 fallen by 97.83%
- Quarterly Activities Report and Appendix 4C 31 Oct 2018 5:32PM $0.415 $0.009 fallen by 97.83%

651 - 675 of 891 results

Page 27 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.